We are live on ! Find out more
SLNO

Soleno Therapeutics
SLNO

Delisted

SLNO was delisted on the 15th of May, 2026.

Back to rankings

19 hedge funds and large institutions have $26.4M invested in Soleno Therapeutics in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

29% more capital invested

Capital invested by funds: $20.5M → $26.4M (+$5.89M)

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

6% more funds holding

Funds holding: 18 → 19 (+1)

1.85% more ownership

Funds ownership: 2.96% → 4.81% (+1.8%)

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.42%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
5
Increased
4
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
A
Abingworth
United Kingdom
+$9.09M
2
OIM
Oracle Investment Management
Connecticut
+$2.42M
3
FI
Fosun International
China
+$351K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$235K
5
TMC
Trellus Management Company
Florida
+$32.2K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$439K
2
KC
Kepos Capital
New York
-$81K
3
SAM
Sectoral Asset Management
Quebec, Canada
-$47K
4
SAM
Shikiar Asset Management
New York
-$9.25K
5
BlackRock
BlackRock
New York
-$934
Name Holding Trade Value Shares
Change 		Change in
Stake
A
1
Abingworth
United Kingdom
$7.98M +$9.09M +311,285 New
VC
2
Vivo Capital
California
$7.46M – – –
OIM
3
Oracle Investment Management
Connecticut
$6.3M +$2.42M +83,009 +51%
6CM
4
683 Capital Management
New York
$1.44M – – –
BC
5
Birchview Capital
Vermont
$1.12M – – –
SM
6
Sabby Management
Florida
$906K -$439K -15,026 -30%
Vanguard Group
7
Vanguard Group
Pennsylvania
$320K +$235K +8,061 +183%
FI
8
Fosun International
China
$294K +$351K +12,028 New
TMC
9
Trellus Management Company
Florida
$290K +$32.2K +1,103 +11%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$87K – – –
BlackRock
11
BlackRock
New York
$69K -$934 -32 -1%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$49K – – –
SAM
13
Shikiar Asset Management
New York
$44K -$9.25K -317 -16%
PAM
14
Panagora Asset Management
Massachusetts
$32K +$13.2K +452 +57%
Northern Trust
15
Northern Trust
Illinois
$20K – – –
TRCT
16
Tower Research Capital (TRC)
New York
$4K +$4.55K +156 New
UBS Group
17
UBS Group
Switzerland
$3K +$3.97K +136 New
KC
18
Kepos Capital
New York
– -$81K -2,506 Closed
SAM
19
Sectoral Asset Management
Quebec, Canada
– -$47K -1,439 Closed
Bank of America
20
Bank of America
North Carolina
– -$292 -10 Closed
Morgan Stanley
21
Morgan Stanley
New York
– +$29 +1 New

SLNO Hedge Fund Activity: Q4 2018 in Review

19 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q4 2018, worth a combined $26.4M — up 29% from $20.5M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new SLNO positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.

The largest buyer was Abingworth, opening a new position worth an estimated $9.09M. The largest seller was Sabby Management, cutting an estimated $439K.

  • 19 institutional investors held Soleno Therapeutics (SLNO) as of Q4 2018, up from 18 in Q3 2018.
  • Funds reported $26.4M of Soleno Therapeutics stock for Q4 2018, up 29% quarter-over-quarter.
  • 5 funds opened new Soleno Therapeutics positions in Q4 2018 and 4 closed out, a net change of +1 holder.
  • The largest Soleno Therapeutics buyer in Q4 2018 was Abingworth, an estimated $9.09M added.
  • The largest Soleno Therapeutics seller in Q4 2018 was Sabby Management, an estimated $439K sold.

Based on aggregated 13F filings for Q4 2018.